Literature DB >> 2648922

Performance characteristics of serologic tests for human immunodeficiency virus type 1 (HIV-1) antibody among Minnesota blood donors. Public health and clinical implications.

K L MacDonald1, J B Jackson, R J Bowman, H F Polesky, F S Rhame, H H Balfour, M T Osterholm.   

Abstract

STUDY
OBJECTIVE: To evaluate performance characteristics of sequential enzyme immunoassay (EIA) and Western blot human immunodeficiency virus type 1 (HIV-1) antibody testing in a low-risk population.
DESIGN: Three-year prospective study of a selected sample from a community-based population.
SETTING: Two blood collection facilities in Minnesota. POPULATION: Minnesota blood donors.
RESULTS: During the study period, 630,190 units of blood (donations) from an estimated 290,110 Minnesota-resident donors were screened for HIV-1 antibody. Seventeen Minnesota-resident donors were identified as positive for HIV-1 antibody. Sixteen donors were available for follow-up HIV-1 culture: all were culture positive. The other donor, who was not available for follow-up culture, was likely infected with HIV-1 based on a history of high-risk behavior and positive serologic findings for hepatitis B surface antigen. Using 95% binomial confidence intervals, performance characteristics for sequential EIA and Western blot HIV-1 antibody serology were as follows: false-positive rate by number of donations, 0% to 0.0006%; specificity by number of donations, 99.9994% to 100%; predictive value of a positive test, 81% to 100%.
CONCLUSIONS: In this low-risk population, the false-positive rate of serologic tests for HIV-1 antibody, using HIV-1 culture as the definitive standard for infection status, was extremely low and test specificity was extremely high.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2648922     DOI: 10.7326/0003-4819-110-8-617

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  12 in total

1.  Indeterminate HIV-1 western blots: implications and considerations for widespread HIV testing.

Authors:  C L Celum; R W Coombs
Journal:  J Gen Intern Med       Date:  1992 Nov-Dec       Impact factor: 5.128

2.  Reactivity patterns and infection status of serum samples with indeterminate Western immunoblot tests for antibody to human immunodeficiency virus type 1.

Authors:  E Ramirez; P Uribe; D Escanilla; G Sanchez; R T Espejo
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

3.  Routine HIV testing hits the primary care clinic.

Authors:  Robert L Cook; Gail Berkenblit
Journal:  J Gen Intern Med       Date:  2009-12       Impact factor: 5.128

4.  Evaluation of Chiron HIV-1/HIV-2 recombinant immunoblot assay.

Authors:  R L Kline; D McNairn; M Holodniy; L Mole; D Margolis; W Blattner; T C Quinn
Journal:  J Clin Microbiol       Date:  1996-11       Impact factor: 5.948

Review 5.  Laboratory tests for detection of human immunodeficiency virus type 1 infection.

Authors:  N F Nuwayhid
Journal:  Clin Diagn Lab Immunol       Date:  1995-11

6.  Utility of quantitative enzyme immunoassay reactivity for predicting human immunodeficiency virus seropositivity in low- and high-prevalence populations.

Authors:  X Hou; P L Breese; J M Douglas
Journal:  J Clin Microbiol       Date:  1994-01       Impact factor: 5.948

7.  Evidence-based guidelines for universal counselling and offering of HIV testing in pregnancy in Canada.

Authors:  L Samson; S King
Journal:  CMAJ       Date:  1998-06-02       Impact factor: 8.262

8.  Cost-effectiveness of voluntary HIV screening in Russia.

Authors:  S P Tole; G D Sanders; A M Bayoumi; C M Galvin; T N Vinichenko; M L Brandeau; D K Owens
Journal:  Int J STD AIDS       Date:  2009-01       Impact factor: 1.359

9.  False-positive human immunodeficiency virus antibody test in a dialysis patient.

Authors:  Douglas M Silverstein; Diego H Aviles; V Matti Vehaskari
Journal:  Pediatr Nephrol       Date:  2004-02-26       Impact factor: 3.714

10.  Cost-effectiveness of HIV screening in patients older than 55 years of age.

Authors:  Gillian D Sanders; Ahmed M Bayoumi; Mark Holodniy; Douglas K Owens
Journal:  Ann Intern Med       Date:  2008-06-17       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.